Gennaro Daniele

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.

Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.

Journal: Journal of the National Cancer Institute

Published: April 09, 2026

Temporal patterns and factors associated with early termination in phase 1 clinical trials for solid tumors.

Temporal patterns and factors associated with early termination in phase 1 clinical trials for solid tumors.

Journal: Journal of the National Cancer Institute

Published: December 22, 2025

Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression.

Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression.

Journal: ESMO open

Published: November 14, 2025

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: October 17, 2025

Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies.

Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies.

Journal: The journal of liquid biopsy

Published: October 08, 2025

Investigational sites requirements according to trial complexity and intervention level under EU Regulation No. 536/2014.

Investigational sites requirements according to trial complexity and intervention level under EU Regulation No. 536/2014.

Journal: Journal of cancer policy

Published: October 05, 2025

Artificial intelligence in oncology publishing: a systematic review and policy analysis of high-impact journals.

Artificial intelligence in oncology publishing: a systematic review and policy analysis of high-impact journals.

Journal: Frontiers in oncology

Published: October 01, 2025

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 12, 2025

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal: Journal of hepatology

Published: September 04, 2025

Main factors associated with variability in the assessment of the objective response rate. A re-analysis of the PHEREXA phase 3 clinical trial.

Main factors associated with variability in the assessment of the objective response rate. A re-analysis of the PHEREXA phase 3 clinical trial.

Journal: British journal of clinical pharmacology

Published: July 25, 2025

Current landscape of T-cell engagers in early-phase clinical development in solid cancers.

Current landscape of T-cell engagers in early-phase clinical development in solid cancers.

Journal: Frontiers in immunology

Published: July 14, 2025

The Role of Social Media in Fueling Bias in Oncology.

The Role of Social Media in Fueling Bias in Oncology.

Journal: JAMA oncology

Published: April 24, 2025

Showing 1-12 of 92

Last Updated: 09/26/2026